The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
Portfolio Pulse from
The Schall Law Firm has announced a class action lawsuit against Regeneron Pharmaceuticals, Inc. for alleged securities fraud. Investors who purchased Regeneron securities between November 2, 2023, and October 30, 2024, are invited to join the lawsuit.
February 22, 2025 | 3:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Regeneron Pharmaceuticals is facing a class action lawsuit for alleged securities fraud, which could negatively impact its stock price in the short term.
The announcement of a class action lawsuit for securities fraud is likely to negatively impact Regeneron's stock price as it raises concerns about the company's compliance with securities laws and potential financial liabilities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100